TR201904655T4 - Piridilaminoasetik asit bileşiği. - Google Patents

Piridilaminoasetik asit bileşiği. Download PDF

Info

Publication number
TR201904655T4
TR201904655T4 TR2019/04655T TR201904655T TR201904655T4 TR 201904655 T4 TR201904655 T4 TR 201904655T4 TR 2019/04655 T TR2019/04655 T TR 2019/04655T TR 201904655 T TR201904655 T TR 201904655T TR 201904655 T4 TR201904655 T4 TR 201904655T4
Authority
TR
Turkey
Prior art keywords
acid compound
pyridylaminoacetic acid
pyridylaminoacetic
asthma
therapeutic
Prior art date
Application number
TR2019/04655T
Other languages
English (en)
Inventor
Iwamura Ryo
Tanaka Masayuki
Katsube Tetsushi
Shigetomi Manabu
Okanari Eiji
Tokunaga Yasunori
Fujiwara Hiroshi
Original Assignee
Ube Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41065261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201904655(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ube Industries filed Critical Ube Industries
Publication of TR201904655T4 publication Critical patent/TR201904655T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Mevcut buluş, şu formül (1) ile temsil edilen yeni bir piridilaminoasetik asit bileşiği: (burada R1, R2, R3, Y ve Z, tarifname ve istemlerde tanımlanan şekildedir), veya bunun farmakolojik olarak kabul edilebilir bir tuzunu sağlamaktadır. Piridilaminoasetik asit bileşiği, EP2 agonistik eyleme sahiptir ve bu nedenle astım veya kronik obstrüktif pulmoner hastalık gibi respiratuar hastalıklar için bir terapötik ve/veya profilaktik ajan olarak yararlıdır.
TR2019/04655T 2008-03-12 2009-03-12 Piridilaminoasetik asit bileşiği. TR201904655T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008062926 2008-03-12

Publications (1)

Publication Number Publication Date
TR201904655T4 true TR201904655T4 (tr) 2019-06-21

Family

ID=41065261

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/04655T TR201904655T4 (tr) 2008-03-12 2009-03-12 Piridilaminoasetik asit bileşiği.

Country Status (18)

Country Link
US (2) US8648097B2 (tr)
EP (1) EP2264009B1 (tr)
JP (3) JP5136640B2 (tr)
KR (1) KR101609001B1 (tr)
CN (2) CN101970410B (tr)
AU (1) AU2009224329B2 (tr)
CA (1) CA2718393C (tr)
CY (1) CY1121543T1 (tr)
DK (1) DK2264009T3 (tr)
ES (1) ES2718813T3 (tr)
HR (1) HRP20190509T1 (tr)
HU (1) HUE042839T2 (tr)
LT (1) LT2264009T (tr)
PL (1) PL2264009T3 (tr)
PT (1) PT2264009T (tr)
SI (1) SI2264009T1 (tr)
TR (1) TR201904655T4 (tr)
WO (1) WO2009113600A1 (tr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201904655T4 (tr) 2008-03-12 2019-06-21 Ube Industries Piridilaminoasetik asit bileşiği.
KR101681347B1 (ko) * 2009-03-30 2016-11-30 우베 고산 가부시키가이샤 녹내장의 치료 또는 예방을 위한 의약 조성물
WO2011030871A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 Ｎ－置換ヘテロアリール化合物
WO2011030864A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 アニリン化合物
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
WO2011030872A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 スルホンアミド化合物
WO2011030873A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 ベンジル化合物
WO2011030865A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 置換ベンジル化合物
US20120226036A1 (en) * 2009-09-11 2012-09-06 Ube Industries, Ltd. Substituted carbonyl compound
JPWO2011078303A1 (ja) * 2009-12-25 2013-05-09 宇部興産株式会社 アミノピリジン化合物
US8841458B2 (en) 2010-03-12 2014-09-23 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
JP2013522274A (ja) 2010-03-18 2013-06-13 バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー 非生物的な植物ストレスに対する活性剤としてのアリールスルホンアミド類及びヘタリールスルホンアミド類
EP2471363A1 (de) 2010-12-30 2012-07-04 Bayer CropScience AG Verwendung von Aryl-, Heteroaryl- und Benzylsulfonamidocarbonsäuren, -carbonsäureestern, -carbonsäureamiden und -carbonitrilen oder deren Salze zur Steigerung der Stresstoleranz in Pflanzen
AU2014244926A1 (en) * 2013-03-28 2015-11-12 Ube Industries, Ltd. Substituted biaryl compound
US20160213657A1 (en) * 2013-09-02 2016-07-28 Ube Industries, Ltd. Pharmaceutical composition for treatment and/or prevention of pulmonary disease
TWI650127B (zh) 2014-01-10 2019-02-11 日商參天製藥股份有限公司 含吡啶基胺基乙酸化合物之醫藥組成物
EA031723B1 (ru) 2014-01-10 2019-02-28 Сантэн Фармасьютикал Ко., Лтд. Фармацевтическая композиция, содержащая соединение пиридиламиноуксусной кислоты и полиоксиэтиленовое касторовое масло
CN105899209B (zh) 2014-01-10 2018-09-11 参天制药株式会社 含有吡啶基氨基乙酸化合物的药物制剂
JP6572890B2 (ja) * 2014-06-10 2019-09-11 宇部興産株式会社 ヘテロ芳香族スルホンアミド化合物の製造方法
US10774072B2 (en) 2014-06-10 2020-09-15 Ube Industries, Ltd. Crystal of N-substituted sulfonamide compound
CA2951784C (en) 2014-06-10 2022-05-31 Ube Industries, Ltd. N-substituted sulfonamide compound and method for producing same
JP2017206445A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 呼吸器疾患の治療及び／又は予防のための医薬組成物
JP2017206443A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 置換ビアリール化合物及び他の医薬の組み合わせ
TWI794140B (zh) 2015-07-09 2023-03-01 日商參天製藥股份有限公司 含有吡啶基胺基乙酸化合物之預防及/或治療劑
WO2018108627A1 (de) 2016-12-12 2018-06-21 Bayer Cropscience Aktiengesellschaft Verwendung substituierter indolinylmethylsulfonamide oder deren salze zur steigerung der stresstoleranz in pflanzen
WO2019025153A1 (de) 2017-07-31 2019-02-07 Bayer Cropscience Aktiengesellschaft Verwendung von substituierten n-sulfonyl-n'-aryldiaminoalkanen und n-sulfonyl-n'-heteroaryldiaminoalkanen oder deren salzen zur steigerung der stresstoleranz in pflanzen
TWI842679B (zh) 2017-09-29 2024-05-21 日商參天製藥股份有限公司 含有吡啶基胺乙酸化合物之醫藥
EP3730143A4 (en) 2017-12-21 2021-08-18 Santen Pharmaceutical Co., Ltd. OMIDENEPAG COMBINATION
CA3087019A1 (en) 2017-12-28 2019-07-04 Santen Pharmaceutical Co., Ltd. Pharmaceutical preparation containing pyridyl aminoacetic acid compound
CN118084895B (zh) * 2024-02-28 2025-09-05 中国药科大学 一种一氧化氮供体型Omidenepag衍生物及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0532701A4 (en) 1990-06-08 1993-07-14 Sps Technologies, Inc. Improved magnetic materials and process for producing the same
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
DE69934093T2 (de) 1998-01-27 2007-06-21 Aventis Pharmaceuticals Inc. SUBSTITUIERTE OXOAZAHETEROCYCLYL FAKTOR Xa HEMMER
AU2001290250A1 (en) 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
NZ531153A (en) * 2001-08-09 2005-10-28 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
DE60118628T2 (de) 2001-10-26 2007-02-15 Allergan, Inc., Irvine Omega-cycloalkyl 17-heteroaryl prostaglandin e2 analogen als ep2-rezeptor agonisten
PY0300568A (es) * 2002-01-31 2004-10-01 Pfizer Prod Inc Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi)acetico
EP1481976B1 (en) * 2002-03-05 2012-11-07 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
JP2006519250A (ja) * 2003-03-04 2006-08-24 ファイザー・プロダクツ・インク 医療処置におけるｅｐ２選択的受容体アゴニストの使用
GB0329620D0 (en) 2003-12-22 2004-01-28 Pharmagene Lab Ltd EP2 receptor agonists
WO2005072743A1 (ja) 2004-01-30 2005-08-11 Ono Pharmaceutical Co., Ltd. 気管支拡張剤
JP2007186424A (ja) 2004-11-26 2007-07-26 Ono Pharmaceut Co Ltd 気管支拡張剤
US7994196B2 (en) 2004-02-12 2011-08-09 Mitsubishi Tanabe Pharma Corporation Indazole compound and pharmaceutical use thereof
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
EP1765332A2 (en) 2004-06-17 2007-03-28 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
GB0415320D0 (en) * 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
CA2593439C (en) 2005-01-14 2014-02-25 F. Hoffmann-La Roche Ag Thiazole-4-carboxamide derivatives as mglur5 antagonists
WO2006106711A1 (ja) 2005-03-30 2006-10-12 Eisai R & D Management Co., Ltd. ピリジン誘導体を含有する抗真菌剤
AU2006275263A1 (en) 2005-08-03 2007-02-08 Merck Frosst Canada Ltd EP4 receptor agonist, compositions and methods thereof
US8080567B2 (en) * 2005-08-09 2011-12-20 Asterand Uk Limited EP2 receptor agonists
US7696235B2 (en) * 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
NZ573964A (en) * 2006-07-28 2010-11-26 Pfizer Prod Inc isopropyl [3-({[4-(1H-pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)-amino}methyl)phenoxy]acetate, a prostaglandin E2 receptor agonist (EP2), useful in lower intraocular pressure thereby treating glaucoma
UA94953C2 (en) * 2006-07-28 2011-06-25 Пфайзер Продактс Инк. Ep2 agonists
TR201904655T4 (tr) 2008-03-12 2019-06-21 Ube Industries Piridilaminoasetik asit bileşiği.
KR101681347B1 (ko) 2009-03-30 2016-11-30 우베 고산 가부시키가이샤 녹내장의 치료 또는 예방을 위한 의약 조성물

Also Published As

Publication number Publication date
US20140113907A1 (en) 2014-04-24
ES2718813T3 (es) 2019-07-04
US20110054172A1 (en) 2011-03-03
AU2009224329B2 (en) 2013-11-07
JP5136640B2 (ja) 2013-02-06
CN103965099A (zh) 2014-08-06
CN101970410B (zh) 2014-06-25
DK2264009T3 (en) 2019-04-15
US8648097B2 (en) 2014-02-11
SI2264009T1 (sl) 2019-05-31
KR20100123903A (ko) 2010-11-25
JP2014177476A (ja) 2014-09-25
WO2009113600A1 (ja) 2009-09-17
CA2718393C (en) 2015-06-16
EP2264009A1 (en) 2010-12-22
PT2264009T (pt) 2019-04-29
LT2264009T (lt) 2019-04-25
KR101609001B1 (ko) 2016-04-04
AU2009224329A1 (en) 2009-09-17
CN101970410A (zh) 2011-02-09
CY1121543T1 (el) 2020-05-29
HUE042839T2 (hu) 2019-07-29
JP2013063994A (ja) 2013-04-11
EP2264009B1 (en) 2019-03-06
JP5545344B2 (ja) 2014-07-09
CA2718393A1 (en) 2009-09-17
JPWO2009113600A1 (ja) 2011-07-21
PL2264009T3 (pl) 2019-07-31
EP2264009A4 (en) 2012-08-01
HRP20190509T1 (hr) 2019-05-03

Similar Documents

Publication Publication Date Title
CY1121543T1 (el) Ενωση πυριδυλαμινοοξεικου οξεος
GEP201706735B (en) Kinase inhibitors
ECSP14013173A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida
MY154895A (en) Pyrimidine hydrazide compounds as pgds inhibitors
TNSN08104A1 (en) Pyrimidine amide compounds as pgds inhibitors
GEP20146125B (en) Aminopyrimidines as syk inhibitors
GEP20156216B (en) Heterocyclic compound and usage thereof
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
CY1118173T1 (el) 5-[(3,3,3-τριφθορο-2-υδροξυ-1-αρυλπροπυλ)αμινο]-1h-κινολιν-2-ονες, μια διεργασια για την παραγωγη τους και η χρηση τους ως αντι-φλεγμονωδων παραγοντων
MX2010009401A (es) Forma cristalina de derivado de fenilamino pirimidina.
UA107784C2 (en) Inhibitor of melanin production
ECSP099806A (es) Oxazolidinonas sustituidas y su uso
GB0510584D0 (en) Organic compounds
IN2014DN05772A (tr)
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
CY1116824T1 (el) Ενωσεις πυρουβαμιδιου ως αναστολεις της αλλεργιογονου πεπτιδασης ομαδας 1 των ακαρεων σκονης
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
MX350862B (es) Acidos de piperidinil naftilacetico.
EA201170828A1 (ru) Конденсированные гетероциклические производные оксадиазола, подходящие для лечения рассеянного склероза
DE502005008057D1 (de) Substituierte cyclopenten-verbindungen
JP2011500575A5 (tr)
EA201100502A1 (ru) Гликозидные производные и их применения
MX2013010006A (es) Derivados de sec-hidroxiciclohexilo como inhibidores de lipasa sensible a hormonas (hsl) para el tratamiento de diabetes.
UA114008C2 (xx) Похідні етинілу як модулятори активності рецептора mglur5